Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure - Clinical Lymphoma, Myeloma and Leukemia
British Journal of Haematology | Wiley Online Library
The Korean Journal of Internal Medicine
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
Multiple Myeloma in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 10 (2011)
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial - The Lancet Haematology
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study - The ...
Benefits of additional cycles of bortezomib/thalidomide/dexamethason
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
![PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/96c7781d6fa4259ed9eba04dca6683938899d098/3-Table2-1.png "PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar")
PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial - The Lancet
CASSIOPEIA part 2 | Int'l Myeloma Foundation
Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation. - ppt download
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
Darzalex ®▽ (daratumumab) approved for reimbursement in Ireland in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible - Hospital Professional News
VTd Vs Vd Vs VMP - Multiple Myeloma Clinical Trials
Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia - Biology
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
![PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/96c7781d6fa4259ed9eba04dca6683938899d098/3-Table4-1.png "PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar")
PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar
Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation. - ppt download
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma: Hematology: Vol 12, No 3
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
CONSORT diagram of patients in the trial. VTD, bortezomib, thalidomide,... | Download Scientific Diagram
